Literature DB >> 11738749

Immunogenicity and protective efficacy of a vaccine prepared from 53 kDa truncated hepatitis E virus capsid protein expressed in insect cells.

M Zhang1, S U Emerson, H Nguyen, R E Engle, S Govindarajan, J L Gerin, R H Purcell.   

Abstract

Hepatitis E virus (HEV) is an enterically transmitted virus that causes acute hepatitis. Expression of recombinant HEV capsid protein in insect cells results in two major proteolytically-processed products of 56 and 53kDa which consist of amino acids (aa) 112-607 and 112-578, respectively. The only neutralization epitope identified to date is located at least partially between amino acids 578 and 607 meaning it should be present only in the 56 and not in the 53kDa protein. Previously, it was shown that vaccination with the 56kDa protein greatly reduced virus shedding and protected Rhesus monkeys from hepatitis E when challenged with a high intravenous dose of homologous or heterologous HEV. To evaluate the immunogenicity and protective efficacy of the 53kDa protein, we vaccinated Rhesus monkeys with this protein and challenged them with a high or low dose of homologous virus. Vaccination with the 53kDa protein greatly reduced virus shedding but did not protect against hepatitis following the high dose challenge. Virus was not detected in the vaccinated animals following the low dose challenge, suggesting that sterilizing immunity may have been achieved.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11738749     DOI: 10.1016/s0264-410x(01)00399-1

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  24 in total

Review 1.  Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins.

Authors:  Xiao Zhang; Lu Xin; Shaowei Li; Mujin Fang; Jun Zhang; Ningshao Xia; Qinjian Zhao
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Cloning and expression of truncated ORF2 as a vaccine candidate against hepatitis E virus.

Authors:  Dibya Rani; Rahul Saxena; Baibaswata Nayak; Sudha Srivastava
Journal:  3 Biotech       Date:  2018-09-15       Impact factor: 2.406

Review 3.  Diagnosis of hepatitis E.

Authors:  Rakesh Aggarwal
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-10-02       Impact factor: 46.802

Review 4.  Host immune status and response to hepatitis E virus infection.

Authors:  Lisa J Krain; Kenrad E Nelson; Alain B Labrique
Journal:  Clin Microbiol Rev       Date:  2014-01       Impact factor: 26.132

5.  T-cell epitope mapping of ORF2 and ORF3 proteins of human hepatitis E virus.

Authors:  R Aggarwal; R Shukla; S Jameel; S Agrawal; P Puri; V K Gupta; A P Patil; S Naik
Journal:  J Viral Hepat       Date:  2007-04       Impact factor: 3.728

Review 6.  Nonhuman primate models of human viral infections.

Authors:  Jacob D Estes; Scott W Wong; Jason M Brenchley
Journal:  Nat Rev Immunol       Date:  2018-06       Impact factor: 53.106

Review 7.  Hepatitis E: an overview and recent advances in vaccine research.

Authors:  Ling Wang; Hui Zhuang
Journal:  World J Gastroenterol       Date:  2004-08-01       Impact factor: 5.742

Review 8.  New perspectives on hepatitis E.

Authors:  Kenneth C Hyams
Journal:  Curr Gastroenterol Rep       Date:  2002-08

9.  A truncated hepatitis E virus ORF2 protein expressed in tobacco plastids is immunogenic in mice.

Authors:  Yuan-Xiang Zhou; Maggie Yuk-Ting Lee; James Ming-Him Ng; Mee-Len Chye; Wing-Kin Yip; Sze-Yong Zee; Eric Lam
Journal:  World J Gastroenterol       Date:  2006-01-14       Impact factor: 5.742

Review 10.  Hepatitis E, a vaccine-preventable cause of maternal deaths.

Authors:  Alain B Labrique; Shegufta S Sikder; Lisa J Krain; Keith P West; Parul Christian; Mahbubur Rashid; Kenrad E Nelson
Journal:  Emerg Infect Dis       Date:  2012-09       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.